



Centre for Vaccine Development (CVD Mali)
Meningitis Vaccine Project (MVP)
Scientific Meeting - Wednesday, 10th September 2014
Radisson Blu Hotel, Bamako, Mali

Background

The new meningococcal A (MenA) conjugate vaccine, MenAfriVac[®], has been introduced at public-health scale in several countries of the African meningitis belt and more than 153 million people, 1 to 29 years of age, have received the vaccine to date. Mali was among the three countries where MenAfriVac was first introduced in 2010. To maintain population immunity in all countries following the initial mass vaccination campaigns with MenAfriVac, a sustainable strategy needs to be defined for immunization of new birth cohorts. Countries will have the option of protecting new birth cohorts through routine immunization, catch-up campaigns, or a mixed approach. Towards this effort, the Meningitis Vaccine Project (MVP, a PATH/WHO partnership) and partners conducted two clinical studies in infants to evaluate the MenA conjugate vaccine safety and immunogenicity, optimal vaccine dosage, and co-administration with other routine vaccines used as part of the Expanded Programme on Immunization (EPI).

The MVP first infant study was conducted in Ghana between 2008 and 2012. The second MVP infant study, PsA-TT-007, was conducted by the CVD Mali from March 2012 to September 2013. The results of these studies are crucial to inform strategies and policies for routine immunization with the meningococcal A conjugate vaccine in meningitis belt countries. CVD Mali also conducted another MVP study to assess the duration of vaccine-induced antibodies 4 to 5 years following the administration of a single dose of the MenA conjugate vaccine in 1-29 year olds.

The purpose of this scientific meeting is to share and discuss these results with the Malian Health Authorities and Scientific Leaders. The meeting will illustrate the development of the vaccine, with emphasis on the clinical trials and follow-up studies conducted in Mali, and the progress made with vaccine introduction. Delegates from the Ministry of Health will report on the vaccine introduction campaigns conducted in Mali in 2010-2011. We hope that the meeting outcome will inform public health decision makers and stakeholders on proposed strategies for sustainable immunity against MenA disease.

The meeting will be hosted by the CVD-Mali General Director and Principal Investigator, Professor Samba O. Sow, in collaboration with international experts from the MVP, the WHO and their partners. The meeting is scheduled to take place on 10 September 2014 in Bamako, Mali and will be followed by a community meeting on 11 September, in order to share the results and thank the participating communities.



Provisional Agenda

09:00 - 09:30	MEETING REGISTRATION	
First Session	Chair: Professeur Ousmane Doumbia MSHP (Ministry of Public Health and Hygiene)	
09:30 - 09:50	<i>Welcome remarks</i>	MVP Director
	<i>Opening Remarks</i>	WHO Representative in Mali Minister of Health or Representative
09:50 - 10:00	<i>Role of CVD-Mali in Public Health with a focus on clinical research and vaccine development</i>	Samba O. Sow
10:00 - 10:45	<i>The Meningitis Vaccine Project (MVP), overview</i>	Marie-Pierre Préziosi
	<i>Vaccine development in Serum Institute of India (SIIL), MenAfriVac[®] as a case study</i>	TBC
	<i>The MenAfriVac[®] Development</i>	Godwin Enwere
10:45-11:00	<i>Discussion</i>	All
11:00-11:30	COFFEE BREAK	
Second Session	Chair: Dr Binta Keita MSHP/DNS (National Direction of Health)	
11:30-12:15	<i>The MenAfriVac[®] Introduction</i>	Mamoudou Harouna Djingarey
	<i>The MenAfriVac[®] Introduction in Mali and after</i>	National Direction of Health, Ministry of Health, Mali
	<i>MenAfriVac[®] use in a Controlled Temperature Chain (CTC)</i>	Mamoudou Harouna Djingarey



12:15-12:45	<p><i>Design and implementation of the MVP PsA-TT-007 clinical study conducted at CVD Mali (2012-2013)</i></p> <p><i>Operational aspects of the MVP study conducted at CVD-Mali</i></p>	<p>CVD Team</p> <p>MVP team Agence de Recherche en Santé Humaine (AARSH) team</p>
12:45-13:00	<i>Discussion</i>	All
13:00-14:00	LUNCH BREAK	
Third Session	Chair: Dr Adam Balla Coulibaly MSHP/DRS (Regional Direction of Health)	
14:00-15:00	<p><i>Cross-study results and overall clinical development data. Safety and Immunogenicity of the PsA-TT vaccine</i></p> <p><i>Results of the MVP PsA-TT-007 clinical study conducted at CVD Mali (2012-2013)</i></p> <p><i>Persistence studies in Mali, Gambia and Senegal</i></p>	<p>Godwin Enwere</p> <p>CVD Team</p> <p>CVD Team</p>
15:00-15:15	<i>Towards a MenAfriVac® pediatric indication</i>	Marie-Pierre Préziosi
15:15-15:30	<i>Discussion</i>	All
15:30-15:45	COFFEE BREAK	
15:45-16:45	<p><i>Communication activities in support of MenAfriVac trials and rollout</i></p> <p><i>Echo from Sikasso: fostering team spirit for science and public health</i></p>	<p>Rodrigue Barry</p> <p>CVD team</p>
16:45-17:00	<i>Summary and closing</i>	All

Meeting rapporteurs: Fadima Cheick Haidara and Adama Manby Keita for CVD-Mali - Enricke Bouma and Marie-Françoise Makadi for MVP